Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain

Hideya Kokubun, Kazuyo Nakamura, Misako Fukawa, Motohiro Matoba, Sumio Hoka, Kazuo Yago

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The demand for oxycodone increases in the treatment of patients with cancer pain, but there is no injection formulation containing oxycodone as a single ingredient in Japan. Instead, we have an oxycodone/hydrocotarnine compound product. Long ago, hydrocotarnine was added to enhance the analgesic effect of oxycodone. However, the mechanism of hydrocotarnine is unclear, and few studies have mentioned the conversion ratio between intravenous and oral oxycodone. In the present study, in order to define the conversion ratio between them, we investigated 18 patients treated by intravenous or oral oxycodone and changed to another administration route during their treatment. We surveyed the change in pain level and adverse effects before and after changing the administration route. The conversion ratio from oral oxycodone to intravenous oxycodone/hydrocotarnine was 0.71+/-0.12 (mean+/-S. D.), and no obvious change in adverse effect was observed.

Original languageEnglish
Pages (from-to)2255-2258
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume34
Issue number13
Publication statusPublished - Jan 1 2007

Fingerprint

Oxycodone
Cancer Pain
hydrocotarnine
Analgesics
Japan
Pain
Injections

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain. / Kokubun, Hideya; Nakamura, Kazuyo; Fukawa, Misako; Matoba, Motohiro; Hoka, Sumio; Yago, Kazuo.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 34, No. 13, 01.01.2007, p. 2255-2258.

Research output: Contribution to journalArticle

Kokubun, Hideya ; Nakamura, Kazuyo ; Fukawa, Misako ; Matoba, Motohiro ; Hoka, Sumio ; Yago, Kazuo. / Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2007 ; Vol. 34, No. 13. pp. 2255-2258.
@article{bd730f7f587e4e9fb2ee00ba38e2356a,
title = "Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain",
abstract = "The demand for oxycodone increases in the treatment of patients with cancer pain, but there is no injection formulation containing oxycodone as a single ingredient in Japan. Instead, we have an oxycodone/hydrocotarnine compound product. Long ago, hydrocotarnine was added to enhance the analgesic effect of oxycodone. However, the mechanism of hydrocotarnine is unclear, and few studies have mentioned the conversion ratio between intravenous and oral oxycodone. In the present study, in order to define the conversion ratio between them, we investigated 18 patients treated by intravenous or oral oxycodone and changed to another administration route during their treatment. We surveyed the change in pain level and adverse effects before and after changing the administration route. The conversion ratio from oral oxycodone to intravenous oxycodone/hydrocotarnine was 0.71+/-0.12 (mean+/-S. D.), and no obvious change in adverse effect was observed.",
author = "Hideya Kokubun and Kazuyo Nakamura and Misako Fukawa and Motohiro Matoba and Sumio Hoka and Kazuo Yago",
year = "2007",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "2255--2258",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "13",

}

TY - JOUR

T1 - Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain

AU - Kokubun, Hideya

AU - Nakamura, Kazuyo

AU - Fukawa, Misako

AU - Matoba, Motohiro

AU - Hoka, Sumio

AU - Yago, Kazuo

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The demand for oxycodone increases in the treatment of patients with cancer pain, but there is no injection formulation containing oxycodone as a single ingredient in Japan. Instead, we have an oxycodone/hydrocotarnine compound product. Long ago, hydrocotarnine was added to enhance the analgesic effect of oxycodone. However, the mechanism of hydrocotarnine is unclear, and few studies have mentioned the conversion ratio between intravenous and oral oxycodone. In the present study, in order to define the conversion ratio between them, we investigated 18 patients treated by intravenous or oral oxycodone and changed to another administration route during their treatment. We surveyed the change in pain level and adverse effects before and after changing the administration route. The conversion ratio from oral oxycodone to intravenous oxycodone/hydrocotarnine was 0.71+/-0.12 (mean+/-S. D.), and no obvious change in adverse effect was observed.

AB - The demand for oxycodone increases in the treatment of patients with cancer pain, but there is no injection formulation containing oxycodone as a single ingredient in Japan. Instead, we have an oxycodone/hydrocotarnine compound product. Long ago, hydrocotarnine was added to enhance the analgesic effect of oxycodone. However, the mechanism of hydrocotarnine is unclear, and few studies have mentioned the conversion ratio between intravenous and oral oxycodone. In the present study, in order to define the conversion ratio between them, we investigated 18 patients treated by intravenous or oral oxycodone and changed to another administration route during their treatment. We surveyed the change in pain level and adverse effects before and after changing the administration route. The conversion ratio from oral oxycodone to intravenous oxycodone/hydrocotarnine was 0.71+/-0.12 (mean+/-S. D.), and no obvious change in adverse effect was observed.

UR - http://www.scopus.com/inward/record.url?scp=38849159162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849159162&partnerID=8YFLogxK

M3 - Article

C2 - 18079625

AN - SCOPUS:38849159162

VL - 34

SP - 2255

EP - 2258

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 13

ER -